After Hours Summary: NTRI -28%, VERI -13%, FIT -11%, PEGA +9%, PANW +5% following earnings/guidanceAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: VNCE +9.9% (thinly traded), PEGA +9.3%, THC +8.3%, PANW +5.1%
Companies trading higher in after hours in reaction to news: DPW +8.9% (announces California finance lending license issued to subsidiary), TTS +7.5% (higher after several Directors disclosed insider purchases), HTGM +3.6% (announces the issuance of Australian Patent for 'Methods of Co-detecting mRNA and Small Non-coding RNA'), SN +3.4% (ticking higher after announcing will pay dividends on Series A and B Convertible Perpetual Preferred Stock in cash -previously paid in common stock), DISCA +3.2% (following SNI earnings and ahead of its own earnings release tomorrow before the open), SELB +2% (initiated with Buy/$30 tgt at Mizuho), TSCO +1.8% (initiated with Outperform rating at Bernstein after the close), ACHN +1.2% (after closing near highs - up 15% on the day), CFG +0.8% (says not aware that it is the subject of any active investigation associated with the matter in the earlier press article; reaffirms 2018 outlook), AVGO +0.4% (Qualcomm calls Broadcom comments 'misleading'; Qualcomm has no intention of delaying the annual meeting), HCA +0.4% (following THC results)
Cyber security names are slightly higher following Palo Alto Networks (PANW) earnings/guidance: CYBR +1.6%, etf HACK +1%, FEYE +0.5%After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: NTRI -27.8%, VERI -13.2%, FIT -11.4%, LNTH -8.8%, CRZO -7.8%, EXEL -4.3%, CRC -2.8%
Companies trading lower in after hours in reaction to news: AKRX -35.3% (Fresenius says conducting independent investigation into alleged breaches of FDA data integrity requirements relating to product development at Akorn), TYME -16.2% (commences underwritten public offering of up to 12 million shares of its common stock), NSPR -12.1% (continued weakness - announces after the close a proposed public offering of common stock pursuant to S-3 declared effective on February 23; Company and the Series D Investor entered into a waiver agreement on Feb 26), DBVT -4.2% (light volume after announcing 'positive' prelim results from Phase II study of Viaskin Milk in milk-allergic patients; Company will assess next steps on any potential protocol changes with regulatory authorities), WTW -1.9% (following NTRI results)
